Sri Lanka
Tuberculosis profile
Population  2012 21 million
Estimates of TB burden * 2012 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 1.2 (0.98–1.5) 5.9 (4.7–7.2)
Mortality (HIV+TB only) <0.01 (<0.01–<0.01) 0.02 (0.02–0.03)
Prevalence  (includes HIV+TB) 23 (11–39) 109 (52–185)
Incidence  (includes HIV+TB) 14 (12–17) 66 (55–79)
Incidence (HIV+TB only) 0.017 (0.014–0.02) 0.08 (0.07–0.1)
Case detection, all forms (%) 66 (55–80)    
TB case notifications 2012        
New cases   (%) Retreatment cases (%)
Smear-positive 4 269 (50) Relapse 245 (57)
Smear-negative 1 889 (22) Treatment after failure 74 (17)
Smear-unknown / not done 0 (0) Treatment after default 114 (26)
Extrapulmonary 2 349 (28) Other 0 (0)
Other 0 (0)      
Total new 8 507   Total retreatment 433  
           
Other (history unknown) 403        
Total new and relapse 8 752   Total cases notified 9 343  
New cases Smear-positive Smear-negative/ unknown/
not done
Extrapulmonary
M:F ratio 2.7 1.8 1.3
Age < 15 24 97 188
Laboratories 2012
Smear (per 100 000 population) 1.0
Culture (per 5 million population) 0.7
Drug susceptibility testing (per 5 million population) 0.2
Is second-line drug susceptibility testing available? Yes, outside
country
Treatment success rate 2011 (%)        
New smear-positive and/or culture-positive 87   Is rifampicin used
throughout treatment for
new patients?
Yes
New smear-negative/extrapulmonary 89  
Retreatment 75  
TB/HIV 2012 Number (%)
TB patients with known HIV status 3 379 (36)
HIV-positive TB patients 23 (<1)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 5 (22)
HIV-positive TB patients on antiretroviral therapy (ART) 11 (48)
HIV-positive people screened for TB 599  
HIV-positive people provided with IPT 8  
Estimates of MDR-TB burden 2012*   New   Retreatment
% of TB cases with MDR-TB 0.18 (0–0.99) 2.2 (1–4.1)
MDR-TB cases among notified pulmonary
TB cases
11 (0–61) 10 (4–18)
Reported cases of MDR-TB 2012 New Retreatment Total
Cases tested for MDR-TB 1 069 (23%) 238 (55%) 1 329
Laboratory-confirmed MDR-TB cases 1 4 5
Patients started on MDR-TB treatment     5
Financing TB control 2013
National TB programme budget (US$ millions) 10
% Funded domestically 61%
% Funded internationally 13%
% Unfunded 26%
***
(Rate per 100 000 population per year)
Mortality graph
___ Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
___ Prevalence

(Rate per 100 000 population per year)
Incidence graph
__ Notifications Incidence
___
___ Incidence (HIV+TB only)

Treatment success rate (%)
tx success graph
__ New smear-positive and/or culture-positive
__ New smear-negative/extrapulmonary __
Retreatment

(Number of patients)
CPT ART graph
__ HIV-positive TB patients
__ on CPT __ on ART

Total budget (US$ millions)
Budget funding Graph
__ Funded domestically __ Funded internationally
__ Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 * Ranges represent uncertainty intervals Generated: 2014-04-21 Data: www.who.int/tb/data